A new global partnership to improve surgical care: EORTC 1527 DREAM opens

A landmark collaboration between Europe and Japan, the DREAM study (NCT02781935) (Diffusion-weighted magnetic resonance imaging to assess liver metastasis and improve surgical planning) has officially opened. This first intergroup study between EORTC’s Gastrointestinal Tract Cancer group, Japan Clinical Oncology Group (JCOG) – the leading cancer research network of Japan- and the European Society of Surgical Oncology (ESSO) will assess the accuracy of diffusion-weighted MRI in combination with other diagnostic modalities to predict complete response among patients with borderline resectable/unresectable colorectal liver metastasis who received conversion systemic therapy.

Surgical resection of liver metastasis still offers the best chance for cure for patients with colorectal liver metastasis. Improved imaging modalities and combinations of chemotherapy and targeted therapy have made it possible for patients with complex and extensive liver metastasis to undergo resection. In this process, some metastatic lesions might completely “disappear” in imaging. Whether this corresponds to true pathologic complete response or a durable clinical response is still debated. Thus, the management of “disappearing metastasis” by either resecting or leaving them behind remains a question. DREAM is the first international, multi-center and prospective study to assess the true nature of disappearing metastasis. It is also the first intergroup study between EORTC, ESSO and JCOG, three leaders in the field of cancer treatment and research. This is the first step in developing a tailored treatment for patients, with the objective to potentially decrease the risk of surgical complications.

DREAM will involve 16 European sites, 12 Japanese sites and 2 sites from the United States. An integrated quality assurance program involving surgery, imaging and pathology will be implemented in the study through the SURCARE platform led by EORTC. “DREAM marks the beginning of a dynamic collaboration between EORTC, ESSO and JCOG to develop prospective and innovative surgical clinical research, advocate quality assurance and pave the way for a unique educational exchange of a new generation of young researchers committed to cancer research across Europe and Japan,” said Serge Evrard, SURCARE Principal Investigator and EORTC Board member.

For more information about the collaboration between EORTC and JCOG, please go to

For more information about SURCARE, please go to

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023